Rare cancers
Rare cancers are those with fewer than about 6 new cases per 100,000 people per year. Individually rare, together they are a quarter of all cancers and have worse survival because of late diagnosis, few trials and scattered expertise.
RARECARE (EU) defines rare cancers as incidence <6/100,000/year; there are ~200 such entities making up ~24% of European cancers, with 5-year survival ~48% versus ~63% for common cancers. Causes of the gap: diagnostic delay and misdiagnosis, absence of standard treatments, difficulty running trials (basket/umbrella designs, registries, real-world evidence help), and dispersed care. Responses: European Reference Networks (EURACAN, EuroBloodNet, PaedCan), centralisation (e.g. sarcoma centres), the NCI Rare Tumor Patient Engagement Network, Rare Cancers Europe, orphan-drug incentives and tumour-agnostic approvals (NTRK, MSI-H, RET, BRAF) that serve rare histologies. Paediatric cancers are all rare cancers.
Pages like this
not linked directly; found by shared links- ProductLarotrectinib
Shares Salivary gland cancers, Tumour-agnostic (tissue-agnostic) approval and the tag gap-fill.
- ProductEntrectinib
Shares Salivary gland cancers, Tumour-agnostic (tissue-agnostic) approval and the tag gap-fill.
- ProductPivekimab sunirine
Shares Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and the tag gap-fill.
- TechnologyMultidisciplinary tumour boards
Shares Peking Union Medical College Hospital and the tag gap-fill.
- TermCancer during pregnancy
Shares Gestational trophoblastic neoplasia and the tag gap-fill.
- ProductMitotane
Shares Adrenocortical carcinoma and the tag gap-fill.
- ProductRetifanlimab
Shares Merkel cell carcinoma and the tag gap-fill.
- TechnologyPercutaneous hepatic perfusion (chemosaturation)
Shares Uveal melanoma and the tag gap-fill.